We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

34 hedge funds and large institutions have $1.33M invested in Yarrow Bioscience, Inc. Common Stock in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

0.75% less ownership

Funds ownership: 1.07%0.31% (-0.75%)

23% less funds holding

Funds holding: 4434 (-10)

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

90% less capital invested

Capital invested by funds: $13.4M → $1.33M (-$12M)

Holders
34
Holders Change
-10
Holders Change %
-22.73%
% of All Funds
0.45%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
7
Reduced
5
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
51
Renaissance Technologies
New York
-$17.4K -211 Closed
Northwestern Mutual Wealth Management
52
Northwestern Mutual Wealth Management
Wisconsin
-$18

YARW Hedge Fund Activity: Q3 2025 in Review

34 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q3 2025, worth a combined $1.33M — down 90% from $13.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of YARW and 7 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 7 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $557K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.26M sold.

  • 34 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q3 2025, down from 44 in Q2 2025.
  • Funds reported $1.33M of Yarrow Bioscience, Inc. Common Stock stock for Q3 2025, down 90% quarter-over-quarter.
  • 7 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q3 2025 and 17 closed out, a net change of -10 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q3 2025 was Baker Bros. Advisors, an estimated $557K added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q3 2025 was Cormorant Asset Management, an estimated $2.26M sold.

Based on aggregated 13F filings for Q3 2025.